Staph Infection Medication

Staph Infection MedicationThere is a way to end the cycle of frustrating and excessive expense when yourantibiotic therapy works short-term wonders, but results in chronic problemssoon after treatment is terminated. Delmont's Staphage Lysate (SPL) ® has beenshown to be a highly effective immunotherapeutic when used concurrently withor as a follow-up to antibiotics in the treatment of idiopathic recurrent caninepyoderma.Documented EfficacyIn addition to widespread use in veterinary practices, SPL's value has beenrecorded in controlled studies. Significantly, use of SPL represents a proven wayto avoid extended use of antibiotics.The Professional SolutionWith SPL, your practice gains clients' appreciation for having controlled the dog'spruritic lesions on a long-term basis. Clients also appreciate the saving in time andmoney required by indefinite antibiotic regimens.SPL InformationSPL® is a highly effective bacterial antigen licensed for the treatment of idiopathiccanine pyoderma. It is the only staphylococcal product of its kind approved forcanine use.

Our double blinded study demonstrated a 77% efficacy rate in pyoderma causedby Staphylococcus intermedius.The most important predictor of successful SPL therapy is the selection ofappropriate cases. The dog should have a history of recurrent, idiopathic pyoderma. Its disease should be responsive to antibiotics. All underlying causes should be ruled out (i.e., demodicosis, flea allergy dermatitis, food allergy and hypothyroidism).Recurrent Staphylococcal InfectionsA major concern of veterinary dermatologists has been the recalcitrant nature ofrecurrent pyoderma. Too often - shortly upon the conclusion of an antibiotictreatment modality - staphylococcal skin infection recurs.Traditionally, three treatment programs are utilized by veterinary dermatologists:(1) antibiotics; (2) benzyl peroxide shampoos for the elimination of the staph; and(3) immune-therapy with products such as Staphylococcus Aureus Phage Lysate.Immunostimulants which are frequently used to treat pyoderma have a commonmechanism of enhancing cellular immunity. Cellular immune mechanismsgenerally involve the activation of phagocytes and the stimulation of T cells.Immunological ResearchCurrent immunological research studies indicate that one set of helper T cellsdesignated TH1 is important for providing cell-mediated resistance to infectionwhile TH2 cells provide a humoral response and suppress cell-mediatedresponses. These T cells produce distinctly different regulatory cytokines with TH2cells producing IL-4, IL-5, and IL-l0. 1L-4 has been reported to block IL-2dependent proliferation of T cells and can block macrophage nitric oxidegeneration, which is necessary for killing intracellular parasites.1Recent research by Delmont Laboratories indicates that those cytokines typical ofTH1 cells, IL-2 and interferon gamma, are induced in peripheral blood monocyticcells by Staphage Lysate (SPL)®. These results were reported at the 12th AnnualEuropean Immunology Meeting in Barcelona, Spain, June 1994. TH1 cells have

been found to be vital to the production of cell-mediated resistance to bacterialinfections and particularly important for resistance to chronic skin infections.Our original veterinary canine pyoderma double blinded clinical study saw animprovement in approximately 75% of the cases treated with Staphage Lysate(SPL)®. Those results are consistent with the findings of ongoing surveys of newDelmont Laboratories' veterinary customers in their treatment of caninepyoderma.Human Clinical StudyDelmont Laboratories has recently sponsored a human clinical study on the use ofStaphage Lysate (SPL)® to treat various staphylococcal infections, predominantlythose affecting the skin.During therapy, the number of active peripheral blood phagocytes increased asthe symptoms decreased. A total of 99 patients were treated by six differentphysicians. The conditions treated included impetigo, recurrent furunculosis,atopic eczema, osteomyelitis, otitis media, and hidradenitis suppurativa.2For example - in cases of staphylococcal impetigo - complete clearing of theinfection was observed after an 8 - 12 week period of treatment. These patientshad a substantial increase in the number of active peripheral phagocytes asmeasured by uptake of Candida albicans. The course of therapy and the timerequired to show improvement were similar to that found using Staphage Lysate(SPL)® in cases of canine pyoderma. Delmont Laboratories, Inc 715 Harvard Avenue PO Box 269, Swarthmore, PA 19081 For more information please visit http://www.delmont.com